Allogenica Strengthens Management Team to Drive Growth and Innovation
New Leadership Appointments: Allogenica appoints Tobias Abel, PhD, formerly with Sangamo Therapeutics, as Chief Scientific Officer and...
top of page
VISION
Future-ready Cell Therapy
Allogenica is a preclinical biotech developing affordable immunotherapies in oncology for both solid and liquid tumors.
Allogenica's goal is to provide a universal, "off-the-shelf" cell therapy with the potential to treat all eligible patients with predictable safety and efficacy at drastically reduced manufacturing costs.
A revolution in the field of cell therapy
Chimeric antigen receptor T-cell (CAR-T) therapy is one of the key therapies revolutionizing the healthcare landscape. The approach involves reprogramming immune cells to recognize and kill cancer cells.
But traditional CAR-T therapies, even when truly effective, are long and complex to manufacture, leading to delays that are often too long for patients battling life-threatening diseases.
Unlike traditional CAR-T therapies, Allogenica uses healthy donor hematopoietic stem cells and bioengineers them to express the CAR and treat the patient.
We are committed to making CAR-T therapies universal to bring new cancer treatments to the market that are immediately available to patients, safer and about 10 times less expensive to manufacture.
Our commitment
Inna MENKOVA, PhD
CEO and Co-founder of ALLOGENICA
Allogenica’s unique CAR-T solution
Allogenica has developed unique worldwide expertise:
WHY Allogenica
Our unique approach
Allogenica's unique know-how allows to differentiate stem cells into immature precursor T cells. Allogenica’s innovative CAR-containing vector allows to modify these cells to produce CAR-pre-T.
Allogenica’s most advanced drug candidate is expected to enter clinical trials in 2026.
Allogenica’s CAR-T advantages:
-
High quality of start material
-
Great expansion capacity
-
No exhaustion markers
-
Potency assay
Advantages for bioproduction
-
No Graft vs Host disease (no TCR expression)
-
Long term persistence
-
Efficient thymic maturation
-
Potent anti-cancer activity
Therapeutic advantages
Allogenica’s bioproduction process consists in:
Transferring the CAR gene to these immature cells (called CAR-pre-T cells)
2
Harvesting stem cell from healthy donors
1
After production, CAR-pre-T cells are stored and ready to be delivered "off-the-shelf" when a patient needs them
4
Differentiate and expand the CAR-pre-T cells at large scale in a bioreactor
3
Our Management Team
Inna Menkova, PhD
Chief Executive Officer
and co-founder
Tobias Abel, PhD
Chief Scientific
Officer
Aymeric Bordet
Chief Financial Officer
Board of directors
Chairman of the BOD and co-founder
Jean-Guillaume
Lafay
Board member and co-founder
Jean-Marie Grumel,
MD
President at
33 Californie
Stephane Legastelois, PhD
Investment Manager Pulsalys
Eglantine Rollet,
PhD
Partner, Aloe Private Equity
Jean Pascal
Tranie
Scientific Advisory Board
Latest news
Prof. Charles Dumontet,
MD, PhD
Chairman of the SAB
Prof. Olivier Adotevi,
MD, PhD
Prof. Jean Daniel Lelièvre,
MD, PhD
Julien Marie,
PhD
COLLABORATIONS
They support Allogenica
Join our team
bottom of page